E. Buster

发表

Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?

H. Janssen, E. Buster, 2006, The Netherlands journal of medicine.

Implementation of a regional video multidisciplinary team meeting is associated with an improved prognosis for patients with oesophageal cancer A mixed methods approach.

R. Verhoeven, W. Curvers, G. Nieuwenhuijzen, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Treatment of chronic hepatitis C virus infection - Dutch national guidelines.

R. D. de Knegt, H. Janssen, K. V. van Erpecum, 2008, The Netherlands journal of medicine.

Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions.

A. A. van der Eijk, S. Schalm, E. Buster, 2003, Antiviral research.

Comments on the EASL practice guidelines for the management of chronic hepatitis B: controversies in interferon-based therapy.

H. Janssen, E. Buster, 2009, Journal of hepatology.

Management of hepatitis B virus infected health care workers based on HBV DNA levels.

S. Schalm, E. Buster, 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.

K. Simon, J. Trojan, U. Akarca, 2008, Gastroenterology.

Treatment of chronic hepatitis B virus infection - Dutch national guidelines.

R. D. de Knegt, H. Janssen, K. V. van Erpecum, 2008, The Netherlands journal of medicine.

Chronic Hepatitis B: Individualized Antiviral Therapy

E. Buster, 2009 .

Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients

M. Buti, G. Gerken, H. Janssen, 2009, The American Journal of Gastroenterology.

Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis

M. Buti, C. Niederau, P. Zondervan, 2007, Hepatology.

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

E. Steyerberg, G. Lau, S. Zeuzem, 2009, Gastroenterology.

Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.

A. Uitterlinden, V. Wong, S. Zeuzem, 2012, Gastroenterology.

Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.

H. Janssen, S. Schalm, E. Buster, 2008, Best practice & research. Clinical gastroenterology.

Relapse after treatment with peginterferon α-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B

F. Nevens, H. Janssen, G. Kitis, 2007, Gut.

The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.

J. Drenth, H. Janssen, K. V. van Erpecum, 2012, The Netherlands journal of medicine.

The importance of HBV genotype in HBeAg-positive chronic hepatitis B patients in whom sustained response is pursued.

H. Janssen, E. Buster, 2011, Journal of hepatology.

Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine.

R. D. de Man, P. Zondervan, H. Metselaar, 2008, European journal of gastroenterology & hepatology.

Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline

K. Simon, P. Zondervan, U. Akarca, 2014, Journal of viral hepatitis.

71 POLYMORPHISMS AT RS12979860 AND RS12980275 NEAR PREDICT SEROLOGICAL RESPONSE TO (PEG-)INTERFERON IN HBEAG-POSITIVE CHRONIC HEPATITIS B

V. Wong, H. Janssen, A. Woltman, 2011 .

EASL clinical practice guidelines on the management of chronic hepatitis B: The need for liver biopsy

H. Janssen, E. Buster, 2009 .

Treatment of chronic hepatitis C virus infection - Dutch national guidelines.

R. D. de Knegt, H. Janssen, K. V. van Erpecum, 2008, Netherlands Journal of Medicine.

Prediction of the response to peg‐interferon‐alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

E. Steyerberg, E. Lesaffre, H. Janssen, 2010, Journal of medical virology.

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.

K. Simon, J. Trojan, U. Akarca, 2008, Gastroenterology.

Prolonged antiviral therapy for hepatitis B virus‐infected health care workers: a feasible option to prevent work restriction without jeopardizing patient safety

H. Janssen, A. A. van der Eijk, E. Buster, 2007, Journal of viral hepatitis.